June 4, 2019
Kyowa Hakko Kirin said on June 3 that it has launched a Japan PIII study for its fully human anti-interleukin-17 (IL-17) receptor A antibody Lumicef (brodalumab; development code: KHK4827) targeting an indication of systemic sclerosis. The study is designed to...read more